Latest News - Zoetis
Top Corporates Hub
Zoetis
Zoetis: A Solid Long-Term Buy After Harsh Drawdown
18.08.2026 04:38
Despite aggressive competitor promotions, Zoetis protects industry-leading profitability. Click here to find out why ZTS stock is a Buy.
Zoetis: Another Bad Quarter, Some Value Trap Risk But Shares Still Cheap
16.08.2026 08:45
Zoetisâ mixed Q2 earnings and lowered guidance hit margin of safety, but long-term upside remains. Click for more on ZTS stock.
ZTS Q2 Deep Dive: Leadership Shifts and Competitive Pressures Shape Guidance
10.08.2026 03:25
Animal health company Zoetis (NYSE:ZTS) fell short of the market’s revenue expectations in Q2 CY2026, with sales flat year on year at $2.47 billion. The company’s full-year revenue guidance of $9.22 billion at the midpoint came in 5.4% below analysts’ estimates. Its non-GAAP profit of $1.87 per share was 1% above analysts’ consensus estimates.
Elanco Animal Health Q2 Earnings Call Highlights
08.08.2026 06:03
Elanco Animal Health (NYSE:ELAN) reported second-quarter 2026 revenue of $1.368 billion, up 10% on a reported basis and 8% organically in constant currency, as demand for new pet-health products and strength in U.S. farm animal operations supported growth. Chief Executive Officer Jeff Simmons said
Zoetis (ZTS) Following Earnings And Guidance Cut With A Valuation Question
07.08.2026 16:19
Zoetis earnings, guidance cut and new CFO/COO appointment grab investor attention Zoetis (ZTS) is in focus after reporting second quarter 2026 results that beat earnings per share expectations but came with flat sales, a cut to full year guidance and the appointment of a new CFO/COO. See our latest analysis for Zoetis. The Zoetis share price has reacted positively to the latest earnings and leadership news, with a 1-day share price return of 3.87% and short term gains contrasting with a...
ZTS Q2 Earnings Call Flags Deeper Companion Animal Pressure
07.08.2026 14:00
Zoetis cuts its 2026 outlook as weaker vet traffic, price sensitivity and competition pressure in Companion Animal, while promotions aim to defend share.
Zoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating Officer
06.08.2026 11:00
PARSIPPANY, N.J., August 06, 2026--Zoetis Inc. (NYSE: ZTS) today announced the appointment of James (Jay) Saccaro as Executive Vice President, Chief Financial Officer and Chief Operating Officer, effective August 17, 2026. In this newly created role, Mr. Saccaro will lead Zoetis’ global finance function, shaping capital allocation, financial strategy, reporting and controls, and investor engagement and oversee Global Manufacturing and Supply to drive operational execution and performance. With M
Gear Up for Zoetis (ZTS) Q2 Earnings: Wall Street Estimates for Key Metrics
04.08.2026 13:15
Get a deeper insight into the potential performance of Zoetis (ZTS) for the quarter ended June 2026 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.
How Burry’s Bet and OA Pipeline Push Will Impact Zoetis (ZTS) Investors
04.08.2026 03:16
Recently, investor Michael Burry increased his position in Zoetis, as the company works through competitive pressures and safety concerns around some companion animal osteoarthritis products while advancing 12 pipeline candidates targeting unmet medical needs. Zoetis has also rolled out new osteoarthritis therapies in Canada and the EU, drawing attention to how its innovation pipeline may balance current challenges in its core companion animal portfolio. Next, we’ll examine how Zoetis’...
Zoetis (ZTS) Reports Next Week: Wall Street Expects Earnings Growth
30.07.2026 14:00
Zoetis (ZTS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zoetis (NYSE:ZTS): Dividend Quality Backed by Strong Fundamentals
27.07.2026 08:00
The Best Dividend Stocks screen identifies companies with strong dividends, profitability, and health. Zoetis (ZTS) stands out with a 1.64% yield, 20.56% dividend growth, and low payout ratio.
Zoetis: Sentiment Keeps Winning As Fundamentals Improve
24.07.2026 08:00
Zoetis stock trades ~45% below fair value, despite resilient earnings, a low forward P/E, and a 2.8% dividend yield. Learn more. Click for more on ZTS stock.
Temporary Concerns Present Entry Point in Zoetis (ZTS)
23.07.2026 14:34
Moon Capital Management, LLC, an investment management company, released its second quarter 2025 investor letter. A copy of the letter can be downloaded here. The S&P 500 index rebounded in the second quarter, achieving a 9.6% return for the first half of the year, while Moon Capital Management’s equity portfolio gained 4%. AI-related stocks led […]
Zoetis Inc (NYSE:ZTS): A Top Value Stock with Undervalued Strength
20.07.2026 12:20
Zoetis (ZTS) offers a rare value opportunity with a P/E of 11.83, top-tier profitability, steady growth, and strong cash flow—a compelling buy for disciplined value investors.
Zoetis: An Attractive Risk-Reward Opportunity
17.07.2026 06:33
We have long viewed Zoetis as one of the highest-quality businesses in healthcare, and the company has generally been valued accordingly.
Zoetis Launches Lenivia® (izenivetmab injection) in Canada and the European Union
15.07.2026 12:30
PARSIPPANY, N.J., July 15, 2026--Zoetis Inc. (NYSE: ZTS) today announced that it has recently launched Lenivia® (izenivetmab injection) in Canada and the European Union (EU) member states – a new long-acting monoclonal antibody (mAb) therapy designed to deliver up to three months of osteoarthritis (OA) pain management with a single subcutaneous injection. Backed by a decade of science and research, Lenivia demonstrated a sustained reduction in pain in a pivotal nine-month European field study, w
A Dividend Portfolio That Pays For Your Pets
10.07.2026 16:30
Rescuing a dog or cat can easily turn into a 10- to 20-year financial commitment. Medium-sized dogs often live around 10 to 13 years, while many cats live into their mid-teens and some stretch past 18. The bill that comes with that lifespan is the part many owners never total, because the monthly receipts feel ... A Dividend Portfolio That Pays For Your Pets
Zoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-ND
07.07.2026 11:00
PARSIPPANY, N.J., July 07, 2026--Zoetis Inc. (NYSE: ZTS) today announced that the European Commission (EC) has granted marketing authorization for Poulvac® Procerta® HVT-ND, a recombinant vector vaccine for the protection of chickens against Newcastle disease (ND) and Marek’s disease viruses. The vaccine can be administered either in ovo or by subcutaneous injection at hatch, providing protection against both diseases with a single dose.